Jesse J Swen

List of Publications by Year
in descending order

110 papers	4,343 citations	172457 29 h-index	123424 61 g-index
113 all docs	113 docs citations	113 times ranked	4443 citing authors

#	Article	IF	Citations
1	Dutch Pharmacogenetics Working Group (DPWG) guideline for the geneâ€“drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). European Journal of Human Genetics, 2022, 30, 1105-1113.	2.8	22
2	Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. Clinical Pharmacokinetics, 2022, 61, 231-247.	3.5	9
3	Abnormal Results of Newborn Screening for SCID After Azathioprine Exposure In Utero: Benefit of TPMT Genotyping in Both Mother and Child. Journal of Clinical Immunology, 2022, 42, 199-202.	3.8	6
4	Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. Pharmacogenomics Journal, 2022, 22, 75-81.	2.0	17
5	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. European Journal of Human Genetics, 2022, 30, 1114-1120.	2.8	37
6	UGT1A1 genotype-guided dosing of irinotecan: AÂprospective safety and cost analysis in poor metaboliser patients. European Journal of Cancer, 2022, 162, 148-157.	2.8	27
7	Pharmacogenomic testing in paediatrics: Clinical implementation strategies. British Journal of Clinical Pharmacology, 2022, 88, 4297-4310.	2.4	12
8	Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. Clinical Pharmacology and Therapeutics, 2022, 112, 62-68.	4.7	32
9	A Systematic Review on Diseaseâ€Ðrugâ€Ðrug Interactions with immunomodulating drugs: A Critical Appraisal of Risk Assessment and Drug Labelling. British Journal of Clinical Pharmacology, 2022, , .	2.4	3
10	Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Cancers, 2022, 14, 2838.	3.7	1
11	Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients. British Journal of Clinical Pharmacology, 2022, 88, 4854-4869.	2.4	20
12	Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries. PLoS ONE, 2022, 17, e0268534.	2.5	20
13	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. Clinical Pharmacokinetics, 2021, 60, 89-102.	3.5	6
14	Pharmacogenomic Determinants of Interindividual Drug Response Variability: From Discovery to Implementation. Genes, 2021, 12, 393.	2.4	1
15	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200.	2.0	89
16	Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting. Clinical Pharmacokinetics, 2021, 60, 1201-1215.	3.5	5
17	Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. British Journal of Clinical Pharmacology, 2021, 87, 4262-4272.	2.4	8
18	Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.. Journal of Clinical Oncology, 2021, 39, 3574-3574.	1.6	3

#	Article	IF	Citations
19	Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation. Drug Discovery Today, 2021, 26, 2527-2546.	6.4	12
20	Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. Science Translational Medicine, 2021, 13, .	12.4	42
21	Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice. Frontiers in Pharmacology, 2021, 12, 693453.	3.5	26
22	Substrate specificity of CYP2D6 genetic variants. Pharmacogenomics, 2021, 22, 1081-1089.	1.3	9
23	The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complications. Clinical Chemistry and Laboratory Medicine, 2021, 59, 491-497.	2.3	27
24	Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review. Pharmacogenomics Journal, 2020, 20, 159-168.	2.0	10
25	Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. Clinical Pharmacology and Therapeutics, 2020, 107, 617-627.	4.7	24
26	One nonâ€believer: Response to â€œObviously Nine Believers: Actionable Germline Genetic Variants for Preâ€emptive Pharmacogenetic Testingâ€• Basic and Clinical Pharmacology and Toxicology, 2020, 126, 7-8.	2.5	1
27	Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. Clinical Pharmacology and Therapeutics, 2020, 107, 1240-1255.	4.7	62
28	Standardizing <scp>CYP</scp>2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and Translational Science, 2020, 13, 116-124.	3.1	353
29	Dutch Pharmacogenetics Working Group (DPWG) guideline for the geneâ€“drug interaction of DPYD and fluoropyrimidines. European Journal of Human Genetics, 2020, 28, 508-517.	2.8	127
30	Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines. Frontiers in Pharmacology, 2020, 11, 567048.	3.5	28
31	Precision Medicine Using Pharmacogenomic Panel-Testing. Advances in Molecular Pathology, 2020, 3, 131-142.	0.4	1
32	Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations. Genes, 2020, 11, 1205.	2.4	5
33	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenetics and Genomics, 2020, 30, 131-144.	1.5	26
34	The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients. Frontiers in Pharmacology, 2020, 11, 1142.	3.5	27
35	Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. Journal of Clinical Medicine, 2020, 9, 2890.	2.4	84
36	Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics. Genes, 2020, 11, 1509.	2.4	55

#	Article	IF	Citations
37	Using Personal Genomic Data within Primary Care: A Bioinformatics Approach to Pharmacogenomics. Genes, 2020, 11, 1443.	2.4	8
38	Technologies for Pharmacogenomics: A Review. Genes, 2020, 11, 1456.	2.4	37
39	Exposureâ€“response analysis of endoxifen serum concentrations in early-breast cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 1141-1152.	2.3	10
40	Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework. Journal of Clinical Medicine, 2020, 9, 814.	2.4	20
41	Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. Clinical Pharmacology and Therapeutics, 2019, 106, 313-316.	4.7	14
42	A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 720-737.	2.5	90
43	Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. Pharmacogenomics, 2019, 20, 85-93.	1.3	13
44	Pharmacogenomics Education and Clinical Practice Guidelines. , 2019, , 395-414.		2
45	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics Journal, 2019, 19, 473-479.	2.0	9
46	A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care. European Journal of Human Genetics, 2019, 27, 1532-1541.	2.8	38
47	Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact. Genes, 2019, 10, 416.	2.4	58
48	Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. BMC Medicine, 2019, 17, 110.	5.5	56
49	Development of the <scp>PG</scp>xâ€Passport: A Panel of Actionable Germline Genetic Variants for Preâ€Emptive Pharmacogenetic Testing. Clinical Pharmacology and Therapeutics, 2019, 106, 866-873.	4.7	73
50	A cost analysis of upfront DPYD genotypeâ€“guided dose individualisation in fluoropyrimidine-based anticancer therapy. European Journal of Cancer, 2019, 107, 60-67.	2.8	65
51	Confirmation practice in pharmacogenetic testing; how good is good enough?. Clinica Chimica Acta, 2019, 490, 77-80.	1.1	2
52	Pharmacogenetic Information in Clinical Guidelines: The European Perspective. Clinical Pharmacology and Therapeutics, 2018, 103, 795-801.	4.7	71
53	A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands. Pharmacogenomics, 2018, 19, 311-319.	1.3	16
54	A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 2350-2356.	7.0	7

#	Article	IF	Citations
55	Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 893-898.	4.4	67
56	SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients. Pharmacogenomics, 2018, 19, 613-619.	1.3	2
57	Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clinical Pharmacology and Therapeutics, 2018, 103, 599-618.	4.7	186
58	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 2018, 103, 210-216.	4.7	407
59	Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. Genes, 2018, 9, 585.	2.4	10
60	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. European Journal of Cancer, 2018, 104, 210-218.	2.8	14
61	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncology, The, 2018, 19, 1459-1467.	10.7	238
62	Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients. Pharmacogenomics, 2018, 19, 1195-1202.	1.3	2
63	Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. British Journal of Clinical Pharmacology, 2018, 84, 2889-2902.	2.4	70
64	Implementation of Pharmacogenomics in Everyday Clinical Settings. Advances in Pharmacology, 2018, 83, 219-246.	2.0	33
65	A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.. Journal of Clinical Oncology, 2018, 36, 523-523.	1.6	3
66	A nationwide survey of pharmacistsâ€™ perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. Pharmacogenomics, 2017, 18, 215-225.	1.3	40
67	Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Pharmacogenetics and Genomics, 2017, 27, 223-226.	1.5	5
68	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenetics and Genomics, 2017, 27, 227-231.	1.5	5
69	What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?. Pharmacogenomics, 2017, 18, 1-4.	1.3	1
70	Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. Acta OncolÃ³gica, 2017, 56, 582-589.	1.8	27
71	Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing. Human Mutation, 2017, 38, 310-316.	2.5	69
72	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. European Journal of Cancer, 2017, 86, 226-232.	2.8	13

#	Article	IF	Citations
73	The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen. Pharmacogenomics, 2017, 18, 1125-1132.	1.3	19
74	Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. Pharmacogenomics, 2017, 18, 945-953.	1.3	6
75	The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen. Pharmacogenomics, 2017, 18, 1041-1045.	1.3	19
76	Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. Oncotarget, 2017, 8, 1204-1212.	1.8	6
77	Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients. Pharmacogenomics, 2016, 17, 721-729.	1.3	24
78	A brighter future for the implementation of pharmacogenomic testing. European Journal of Human Genetics, 2016, 24, 1658-1660.	2.8	23
79	Insulin-like growth factor 1 receptor expression and IGF1R 3129Gâ€‰>â€‰T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). Breast Cancer Research, 2016, 18, 3.	5.0	30
80	A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. Expert Review of Molecular Diagnostics, 2016, 16, 605-618.	3.1	19
81	Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. European Journal of Cancer, 2016, 54, 40-48.	2.8	110
82	Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients. Pharmacogenetics and Genomics, 2015, 25, 279-288.	1.5	4
83	Farmacogenetica in uw spreekkamer. Bijblijven (Amsterdam, Netherlands), 2015, 31, 578-588.	0.0	0
84	FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics, 2015, 16, 373-381.	1.3	26
85	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. European Urology, 2015, 68, 621-629.	1.9	75
86	Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics, 2015, 16, 1275-1284.	1.3	81
87	GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population. Pharmacogenomics, 2015, 16, 681-687.	1.3	9
88	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. European Journal of Clinical Pharmacology, 2015, 71, 1477-1484.	1.9	19
89	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genetics in Medicine, 2015, 17, 63-67.	2.4	16
90	CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 4548-4548.	1.6	0

#	Article	IF	Citations
91	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current Drug Metabolism, 2014, 15, 209-217.	1.2	341
92	Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization. Current Drug Metabolism, 2014, 15, 218-232.	1.2	147
93	Pharmacogenetics of taste: turning bitter pills sweet?. Pharmacogenomics, 2014, 15, 111-119.	1.3	6
94	Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule. Internal and Emergency Medicine, 2014, 9, 481-482.	2.0	2
95	Pharmacogenetics in Transplant Patients: Mind the Mix. Clinical Pharmacology and Therapeutics, 2013, 94, 443-444.	4.7	2
96	Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. Pharmacogenomics, 2013, 14, 63-73.	1.3	18
97	Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. Pharmacogenetics and Genomics, 2013, 23, 675-683.	1.5	17
98	Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics, 2013, 14, 1683-1690.	1.3	32
99	Centres of Excellence Course in Pharmacogenetics, 25â€“28 June 2012. European Journal of Hospital Pharmacy, 2013, 20, 132-132.	1.1	0
100	Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics.. Journal of Clinical Oncology, 2013, 31, 4580-4580.	1.6	0
101	The challenges of developing a â€˜medical-gradeâ€™ genome. Pharmacogenomics, 2012, 13, 369-372.	1.3	2
102	Just how feasible is pharmacogenetic testing in the primary healthcare setting?. Pharmacogenomics, 2012, 13, 507-509.	1.3	22
103	Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1Î² gene. Clinical Chemistry and Laboratory Medicine, 2012, 50, 279-84.	2.3	7
104	Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment. Pharmacogenetics and Genomics, 2011, 21, 461-468.	1.5	7
105	SNPs and Haplotypes in DPYD and Outcome of Capecitabineâ€“Letter. Clinical Cancer Research, 2011, 17, 5833-5834.	7.0	5
106	Comment: Global Formulary Review: How Do We Integrate Pharmacogenomic Information?. Annals of Pharmacotherapy, 2011, 45, 1030-1030.	1.9	0
107	Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics, 2010, 11, 1517-1523.	1.3	22
108	Translating Pharmacogenomics: Challenges on the Road to the Clinic. PLoS Medicine, 2007, 4, e209.	8.4	174

#	Article	IF	Citations
109	Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity. Frontiers in Pharmacology, 0, 13, .	3.5	12
110	Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model. Frontiers in Pharmacology, 0, 13, .	3.5	9